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carboplatinAbstract Purpose: The aim of this study was to investigate efﬁcacy and toxicity of the dose-dense
weekly paclitaxel (T) and carboplatin (C) in the management of platinum-resistant/sensitive recur-
rent epithelial ovarian cancer (EOC) previously treated with 3 weekly paclitaxel/carboplatin.
Methods: Thirty two patients with recurrent EOC who had received 3 weekly TC before were
enrolled. Nine patients relapsed within 6 months (platinum-resistant), 13 patients relapsed after
12 months (platinum-sensitive) and in 10 patients recurrence occurred between 6 and 12 months
(intermediate platinum-sensitive). Weekly (T) at a dose of 80 mg/m2, followed by weekly (C)
AUC 2 on day 1, 8, and 15 of a 28-day cycle for 6 planned cycles were administrated. End-points
were overall response rate (ORR), progression free survival (PFS), overall survival (OS) and toxicity.
Results: The ORR was 62.5%. For the platinum-resistant, intermediate platinum-sensitive and
platinum-sensitive patients the ORR was 44.4% (4/9), 60% (6/10) and 76.9% (10/13), respectively,
and 1 (11.1%), 2 (20%) and 5 (38.46%) patients, respectively had CR. PFS was 9.1 months (6.13, 9.1
and 12.17 months, for the 3 groups, respectively) (P< 0.001). OS was 14 months (9.17, 15.2, and
19.23 months, for the 3 groups, respectively) (P< 0.001). Treatment-related adverse events were
manageable with only 1 patient (3.1%) suffering from grade 4 neutropenia. Grade 3 hematological
and non-hematological toxicities were neutropenia in 8 (25%), and peripheral neuropathy in 4
(12.5%) patients, respectively.
Conclusion: Weekly TC is active and well-tolerated in platinum-resistant and platinum-sensitive
patients with recurrent EOC previously treated with TC given every 3 weeks.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
Among gynecologic malignancies, ovarian cancer is the most
deadly [1]. Aggressive cytoreductive surgery, followed by com-
bination of taxane and carboplatin chemotherapy is the stan-
dard of care for EOC with relatively high response rates to
ﬁrst-line platinum-based therapies [2]. Unfortunately, the
majority present with advanced stage disease (75% stage III
& IV). Of these, 70–80% will recur and require second-line
140 H. Shawky et al.palliative chemotherapy in an effort to maintain quality of life
and slow progression of disease [1,3,4].
Platinum progression free interval (PFI) was deﬁned as the
interval between the last platinum-chemotherapy and progres-
sive disease (PD). Platinum-resistant disease was deﬁned as
progression or recurrence within 6 months, while platinum-
sensitivity was deﬁned as recurrence greater than 12 months,
while disease recurrence between 6 and 12 months was deﬁned
as intermediate platinum-sensitive disease [5].
Optimization of pharmacokinetics via manipulation of the
dosing schedule of platinum and taxane has been suggested
as a method of improving response rates in both platinum-sen-
sitive and platinum resistant disease [1]. Weekly dosing exposes
a higher number of cancer cells to cytotoxic treatment during a
critical phase in the cell cycle [6]. The high response rate and
the lack of cardiotoxicity suggest that this regimen should be
considered for future adjuvant therapy [7]. In addition, the
use of weekly paclitaxel may have additional anti-angiogenic
effects when used in a fractionated schedule [8].
Dose-dense weekly paclitaxel plus carboplatin improved
survival compared with the conventional regimen and repre-
sents an active treatment option in women with advanced epi-
thelial ovarian cancer [9]. The noteworthy results stem from
the Japanese Gynecologic Oncology Group (JGOG) trial
3016 which was a large, prospective randomized trial that com-
pared dose-dense weekly paclitaxel plus carboplatin versus the
conventional dosing schedule for those two drugs in the adju-
vant sitting, established a signiﬁcant beneﬁt for both median
overall survival (Median overall survival has not yet been
reached in the dose-dense treatment group, and OS at 5 years
was higher in the dose-dense treatment group than the conven-
tional treatment group (58.6% vs. 51.0%, HR 0.79, 95% CI,
0.63–0.99; P= 0.0448)) and median progression-free survival
(28.2 months vs 17.5 months P= 0.0037) for the dose-dense
treatment group versus the conventional treatment group,
respectively [10].
This entity of platinum-resistant ovarian cancer represents
a different clinical scenario. Several chemotherapeutic agents
such as topotecan, gemcitabine, liposomal doxorubicin, paclit-
axel and etoposide have been used in the treatment of platinum
resistant disease with unexciting disappointed response rates in
the range of 6–15% [11,12]. There is increasing evidence sug-
gesting that the use of extended dose-dense chemotherapy
results in response rates of 40–60% in this otherwise the poor
prognosis group [13,14].
This study was a phase II study to assess the efﬁcacy and
tolerability of weekly paclitaxel at a dose of 80 mg/m2, fol-
lowed by carboplatin AUC 2 on day 1, 8, and 15 of a 28-
day cycle for six planned cycles in female patients with recur-
rent EOC who had received 3 weekly paclitaxel carboplatin
before.Patients and methods
Patient eligibility criteria
Between December 2007 and January 2011, 32 female patients
with recurrent epithelial ovarian cancer (EOC) previously trea-
ted with 3 weekly paclitaxel carboplatin in the Clinical Oncol-
ogy Department, Tanta University Hospital were enrolled.
Patients fulﬁlled the following criteria: age between 18 and70 years, Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 62, adequate bone marrow reserve
(WBC count P3.5 · 109/L, ANC count P1.5 · 109/L, plate-
letsP100 · 109/L, and hemoglobinP10 g/dL), adequate renal
function (measured creatinine clearance P60 mL/min) and
adequate liver function (transaminases less than 2 · upper nor-
mal limit, and serum bilirubin concentrations below 1.5 mg/
dL).
Progressive disease was deﬁned according to modiﬁed
WHO criteria [15]. The new appearance of disease related pleu-
ral effusion or ascites was also considered as progressive
disease.
Patients suffering from secondary malignancy or concur-
rent serious, uncontrolled medical illness (e.g. persistent
immune-compromised states, uncontrolled infection, severe
peripheral neuropathy, and clinically signiﬁcant cardiac dis-
ease) were excluded from this study.
Design of the study
This study is a prospective single-arm phase II single institu-
tion study. The Ethics Committee in the Faculty of Medicine,
Tanta University, granted protocol approval and all patients
signed an informed consent before the initiation of any
treatment.
Treatment plan and dose medication
Weekly paclitaxel at a dose of 80 mg/m2 was delivered as an
intravenous infusion over 60 min (in 500 mL of 5% glucose
solution), followed by carboplatin AUC2 (dissolved in
250 mL 0.9% saline) as an intravenous infusion over 30 min
on day 1, 8, and 15 of a 28-day cycle for six planned cycles.
Chemotherapy was discontinued in case of disease progression
or major toxicities. Cycles were administered on an outpatient
basis. Adequate antiemetic, antacid, antihistaminic and corti-
costeroid therapy were provided for all patients.
Adequate hematological and within normal range organ
functions were insured prior to each cycle. Adverse events were
monitored throughout the study. A complete resolution of
hematologic and non-hematologic toxicity was required except
for alopecia and fatigue. If toxicities did not resolve, then a 1-
week delay was allowed. No prophylactic use of G-CSF was
recommended and in case of grade 3 & 4 neutropenia thera-
peutic and prophylactic use of G-CSF was allowed.
Patient assessment
Assessment of clinical beneﬁt
A tumor response assessment was performed after every three
cycles of treatment. Pre- and on-treatment monitoring con-
sisted of medical history, physical and gynecological examina-
tion, trans-vaginal ultrasound (TVU), CT-scan of the chest,
abdomen and pelvis, and CA125 measurement. Criteria of
complete response, partial response, stable disease and pro-
gressive disease were based on the standard deﬁnitions accord-
ing to modiﬁed WHO criteria [15] with the overall response
rate, including complete response and partial response. An
increase in CA125 levels not associated with radiologic or
clinical evidence of tumor progression was not used as the sole
indicator of progressive disease.
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Toxicity grading was based on the common terminology crite-
ria for adverse event (NCI-CTC, version 3.0) [16].
Primary and secondary endpoints
The primary endpoints of the study were overall response and
toxicity. Secondary end points were the progression-free sur-
vival and overall survival.
Statistical analysis
Thirty-two patients were recruited in the study between
December 2007 and January 2011. Patients were followed up
until December 2013. At the time of analysis, the median fol-
low up duration was 14 months (95% CI; 13.3–14.7 months).
Overall-survival (OS) rates were calculated from the start of
dose-dense weekly paclitaxel (T) and carboplatin (C) to the
time of the last follow-up visit or death using the Kaplan–
Meier method [17] with SPSS [Statistical package] (version
12.0).
Progression-free survival was the time elapsed from
the date of initiation of dose-dense weekly T and C to the
date of ﬁrst evidence of disease progression or death in the
absence of disease progression. The Kaplan–Meier method
[17] is used for estimating survival and log rank for compari-
son of curves. Mean and standard deviation were estimates
of quantitative data. The 95% conﬁdence intervals (95%
CIs) were calculated with the exact method. Fisher exact test
was used for qualitative data and Kruskal–Wallis test was used
for comparing quantitative data for more than 2 groups. All P
values were two-tailed; a value of 60.05 was considered
signiﬁcant.
Results
Patient characteristics
Thirty-two patients were enrolled in the study. The baseline
demographic and clinical characteristics of all enrolled patients
are listed in Table 1. The mean age was 57.1 years, (range; 35–
77 years). Stage III and IV constitute 78.1% of all of the
patients at initial presentation prior to any treatment and 26
patients (81.2%) had serous pathological subtype. Grade III
tumor represented more than half (19 patients, 59.4%). Most
of the patients had ECOG performance status score P1
(71.9%).
Treatment administration
A total of 174 cycles were administrated with a median number
of 5.4 cycles (range 3–6). No dose reduction was recorded and
only 2 patients had dose delay for one week.
Activity of both drugs (patient response to those drugs)
The overall response rate (including complete response and
partial response) was 62.5% (20/32). For the platinum-
resistant, intermediate platinum-sensitive and platinum-
sensitive patients the overall response rate was 44.4% (4/9),60.0% (6/10) and 76.9% (10/13), respectively, and one
(11.1%), 2 (20.0%) and 5(38.5%) patients, respectively, had
complete response (CR, conﬁrmed by PET-study). Stable dis-
ease (SD) was recorded in 2 (22.2%), 2 (20.0%), and 2 (15.3%)
patients of platinum-resistant, intermediate platinum-sensitive
and platinum sensitive patients, respectively, while progressive
disease (PD) was recorded in 3 (33.4%), 2 (20.0%), and 1
(7.7%) patients of platinum-resistant, intermediate platinum
sensitive and platinum sensitive patients, respectively (Table
2). Six patients reported to progress on study protocol.Survival
All our patients were followed up regularly as mentioned pre-
viously in patients and methods, with no one having lost fol-
low up in this study. The median follow up duration was
14 months (95% CI; 13.3–14.7 months).
Median progression free survival (PFS) was 9.1 months
(95% CI 8.1–10.1) (Fig. 1). Median PFS was 6.1, 9.1 and
12.2 months, for platinum-resistant, intermediate platinum-
sensitive and platinum-sensitive patients, respectively (P<
0.001), (Fig. 2).
Twenty four patients died during the observation period.
Median overall survival (OS) was 14 months ± SE 0.35
(range; 4.1–38.5 months), with its 95% CI 13.3–14.7 (Fig. 3).
Median OS was 9.2, 15.2 and 19.2 months for platinum-
resistant, intermediate platinum-sensitive and sensitive plati-
num-patients, respectively (P< 0.001), (Fig. 4).
Toxicity
In our study the toxicity proﬁle of this regimen was well toler-
ated with only one (3.1%) and 8 (25.0%) patients suffering
from grade 4 and grade 3 neutropenia, respectively. Grade 3
anemia occurred in 2 patients (6.3%), and 2 patients (6.3%)
experienced grade 3 thrombocytopenia.
Peripheral neuropathy was the most frequent grade 3 non-
hematological side effects recorded in 4 (12.5%) patients in our
study (Table 3).Discussion
Most of the patients with advanced epithelial ovarian cancer
(EOC) will ultimately recur and require second-line palliative
chemotherapy [18–20]. Second-line palliative chemotherapy
demonstrated advantages over best supportive care for recur-
rent EOC patients, in an effort to maintain an acceptable qual-
ity of life, control symptoms, and prolonging survival if
possible [21–26].
van der Burg et al. [5] reported that the RR in published
series on non-platinum paclitaxel regimen was 16% for pegy-
lated liposomal doxorubicin (PLD), 13% for topotecan in
platinum resistant patients. Sharma et al. [14] reported that
several chemotherapeutic agents such as topotecan, gemcita-
bine, liposomal doxorubicin and etoposide have been used in
the treatment of platinum-resistant disease with unexciting
response rates in the range of 10–15% in this patient group.
Kumar et al. [26], in a review article reported that the best
response rates in platinum-resistant patients have been in the
10–20% range.
Table 1 Demographic characteristics of the 32 patients with platinum-resistant/sensitive recurrent EOC previously treated with 3
weekly paclitaxel/carboplatin at baseline.
Characteristic Type P-value
Platinum resistant Intermediate platinum sensitive Platinum sensitive Total
N= 9 % N= 10 % N= 13 % N= 32 %
Age (years)
Median 60.0 64.0 59.0 60.0 0.243
Mean 57.8 61.4 58.0 57.1
Range 40–71 35–75 38–77 35–77
FIGO stage
Stage I 1 11.1 1 10.0 2 15.4 4 12.5 0.908
Stage II 1 11.1 1 10.0 1 7.7 3 9.4
Stage III 3 33.3 6 60.0 7 53.8 16 50.0
Stage IV 4 44.5 2 20.0 3 23.1 9 28.1
Pathological type
Serous 8 88.9 8 80.0 10 76.9 26 81.2 0.627
Endometriold 1 11.1 0 0.0 1 7.7 2 6.3
Mucinous 0 0.0 1 10.0 1 7.7 2 6.3
Clear cell 0 0.0 1 10.0 1 7.7 2 6.2
ECOG performance status
0 2 22.2 3 30.0 4 30.8 9 28.1 0.968
1 5 55.6 4 40.0 6 46.1 15 46.9
2 2 22.2 3 30.0 3 23.1 8 25.0
Tumor Grade
Grade I 1 11.1 1 10.0 2 15.4 4 12.5 0.800
Grade II 2 22.2 2 20.0 5 38.5 9 28.1
Grade III 6 66.7 7 70.0 6 46.1 19 59.4
Table 2 Tumor response to dose-dense weekly paclitaxel and carboplatin in the management of the 32 patients with platinum-
resistant/sensitive recurrent EOC.
Response Type
Platinum resistant Intermediate platinum sensitive Platinum sensitive Total
N % N % N % N %
Complete response (CR) 1 11.1 2 20.0 5 38.5 8 25.0
Partial response (PR) 3 33.3 4 40.0 5 38.5 12 37.5
Stable disease (SD) 2 22.2 2 20.0 2 15.3 6 18.7
Progressive disease (PD) 3 33.4 2 20.0 1 7.7 6 18.8
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Figure 1 Kaplan–Meier curve of progression-free survival.
Median progression-free survival time was 9.1 months.
142 H. Shawky et al.We used weekly paclitaxel at a dose of 80 mg/m2, followed
by carboplatin AUC 2 on day 1, 8, and 15 of a 28-day cycle for
six planned cycles, unless discontinuation due to sever toxicity
or disease progression, more than 75% of our patients received
6 cycles, and this treatment schedules and doses were selected
based on previous studies [5,14]. This treatment schedule
appeared to have good clinical efﬁcacy (62.5% overall
response rate).
Sharma et al. [14] reported an overall response rate of 60%
for patients who received carboplatin AUC 3 and paclitaxel
70 mg m2 on day 1, 8, and 15 q 4 weekly for six planned cycles
in recurrent EOC patients. This is also consistent with previous
published studies by van der Burg et al. [5] and Cadron et al.
[27] who reported a response rate of 62%, and 66%,
respectively.
The use of extended dose-dense chemotherapy for the
platinum-resistant, intermediate platinum-sensitive and plati-
num-sensitive patients in our study results in an overall
response rate of 44.4% (4/9), 60% (6/10) and 76.9% (10/13),
respectively. van der Burg et al. [5] reported response rate of
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Figure 2 Kaplan–Meier curve of progression-free survival for
platinum-resistant, intermediate platinum-sensitive and platinum-
sensitive patients.
Overall survival in months
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Figure 3 Kaplan–Meier curve of overall survival. Median
overall survival time was 14 months.
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Figure 4 Kaplan–Meier curve of overall survival for platinum-
resistant, intermediate platinum-sensitive and platinum-sensitive
patients.
Table 3 Hematologic and non-hematologic grade 3 & 4
toxicity of the dose-dense weekly paclitaxel and carboplatin in
the management of the 32 patients with platinum-resistant/
sensitive recurrent EOC.
Toxicity Grade 3 no. (%) Grade 4 no. (%)
Non-hematologic toxicity
Anorexia 3 (9.4) 0.0
Stomatitis/pharyngitis 2 (6.3) 0.0
Nausea/vomiting 3 (9.4) 0.0
Peripheral neuropathy 4 (12.5) 0.0
Diarrhea 2 (6.3) 0.0
Hematologic toxicity
Neutropenia 8 (25.0) 1 (3.1)
Anemia 2 (6.3) 0.0
Thrombocytopenia 2 (6.3) 0.0
Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma 14351%, 60% and 61% after the weekly paclitaxel/carboplatin
therapy for the platinum-resistant, intermediate platinum-sen-
sitive and platinum-sensitive patients, respectively. Cadron et
al. [27] reported response rate of 38%, 73% and 80% after
the weekly paclitaxel/carboplatin therapy for the platinum-
resistant, intermediate platinum-sensitive and platinum-sensi-
tive patients, respectively.
In our study, the median progression free survival (PFS)
was 9.1 months (6.1, 9.1 and 12.2 months, for platinum-
resistant, intermediate platinum-sensitive and sensitive
platinum-patients, respectively). Cadron et al. [27] reported a
comparable median progression free survival (PFS) of
9 months (6.8, 10.5 and 12.8 months, for platinum-resistant,
intermediate platinum-sensitive and sensitive platinum-
patients, respectively). However, the median PFS in our study
was better than those reported in other trials which reported
PFS of 5–8 months [13,28,29], and was lower than thosereported in van der Burg et al. [5] study, in which the median
PFS was 8.0, 11.0 and 13.0 months for platinum-resistant,
intermediate platinum-sensitive and sensitive platinum-
patients, respectively.
In our study, the median overall survival (OS) of 14 months
(9.2, 15.2 and 19.2 months, for platinum-resistant, intermedi-
ate platinum-sensitive and sensitive platinum-patients, respec-
tively), was better than those reported in other trials which
reported an OS of 10–11 months [13,28,29], and was lower
than those reported in van der Burg et al. [5] study, in which
the median OS was 15.0, 28.0 and 26.0 months for platinum-
resistant, intermediate platinum-sensitive and sensitive plati-
num-patients, respectively.
Toxicity is an important consideration for patients with
recurrent disease for whom chemotherapy is palliative. In
our study the toxicity proﬁle of this regimen was well tolerated,
with only one (3.1%) and 8 (25.0%) patients suffering from
grade 4 and 3 neutropenia, respectively. Grade 3 anemia
occurred in 2 patients (6.3%), and 2 patients (6.3%) experi-
enced grade 3 thrombocytopenia. The frequency of these tox-
icities was somewhat nearly similar to those reported by
144 H. Shawky et al.Sharma et al. [14] and lower than those reported by van der
Burg et al. study [5]. Sharma et al. [14] administered weekly
paclitaxel at 70 mg/m2 and carboplatin at AUC 3 on day 1,
8, and 15 every 4 weeks in patients with recurrent ovarian can-
cer, and prior treatment with a platinum-agent regimen
recorded that the most common hematological adverse events
were grade 3/4 neutropenia in 30.0%, grade 3 anemia in one
(5.0%) patient and no grade 3 thrombocytopenia. van der
Burg et al. [5] reportedP3 grade neutropenia and thrombocy-
topenia in 40.0% and 8.0% of patients, respectively in the
weekly phase. The addition of G-CSF to avoid neutropenia
and maintain dose intensity, and decrease the incidence of dose
delay was considered in the subsequent cycles.
Interestingly, peripheral neuropathy which was the most
frequent grade 3 non-hematological side effects did not repre-
sent a high incidence rate, only reported in 4 (12.5%) patients
in our study, despite the majority of patients having had prior
treatment with a taxane. Sharma et al. [14] recorded grade 3
neuropathy in 3 (14%) patients.
So, one hour infusion of paclitaxel in weekly schedule is
associated with less neurotoxicity and decrease in dose per
injection of paclitaxel (weekly schedule) also was associated
with a decrease in myelosuppression.Conclusion
Prospective randomized clinical trial incorporating targeted
agents and newer forms of paclitaxel (Abraxane) aimed at
decreasing toxicity, increasing efﬁcacy, improving ease of
administration, and to show if it can reverse acquired clinical
platinum resistance patients if demanded. However limited
resources are an obstacle to be used frequently for recurrent
EOC patients in our country.
The area of recurrent ovarian carcinoma is a hot topic with
ongoing trials evolving and conﬁrming the role of anti-angio-
genic and PARP inhibitor drugs with dose dense taxol carbo-
platin and in order to detect predictive biomarkers to identify
patients most likely to beneﬁt and personalized treatment to
each patient.
From our study, we conclude that, extended dose-dense
carboplatin/paclitaxel regimen with ‘3 weeks on, 1 week off’
affords the opportunity to treat effectively and safely with min-
imal toxicity in heavily pretreated EOC patients. This ﬁnding
is of importance as platinum resistance ultimately becomes
the dominant problem for most patients with ovarian cancer.
However ﬁnal conclusions about the superiority of our regi-
men for platinum resistant disease needed prospective random-
ized studies with larger numbers of patients to be analyzed.Conﬂict of interest
The authors have no conﬂict of interest to declare.
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